Alexion Pharmaceuticals Verschuldung / Eigenkapital
Was ist das Verschuldung / Eigenkapital von Alexion Pharmaceuticals?
Verschuldung / Eigenkapital von Alexion Pharmaceuticals Inc. ist 1.50
Was ist die Definition von Verschuldung / Eigenkapital?
Die Verschuldung zu Eigenkapital ist ein Finanzverhältnis, das den relativen Anteil des Eigenkapitals und der Verschuldung angibt, die zur Finanzierung der Vermögenswerte eines Unternehmens verwendet werden.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Verschuldung / Eigenkapital von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Alexion Pharmaceuticals
Was macht Alexion Pharmaceuticals?
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Unternehmen mit verschuldung / eigenkapital ähnlich Alexion Pharmaceuticals
- Affluent Foundation hat Verschuldung / Eigenkapital von 1.50
- Volex plc hat Verschuldung / Eigenkapital von 1.50
- KBL Merger IV hat Verschuldung / Eigenkapital von 1.50
- National Research Corp hat Verschuldung / Eigenkapital von 1.50
- Arvind SmartSpaces hat Verschuldung / Eigenkapital von 1.50
- MCI Onehealth Technologies hat Verschuldung / Eigenkapital von 1.50
- Alexion Pharmaceuticals hat Verschuldung / Eigenkapital von 1.50
- Liquidia Corp hat Verschuldung / Eigenkapital von 1.50
- China International Marine Containers () Co hat Verschuldung / Eigenkapital von 1.50
- SQL Ingénierie SA hat Verschuldung / Eigenkapital von 1.50
- Sino-Life hat Verschuldung / Eigenkapital von 1.50
- Ulta Beauty Inc hat Verschuldung / Eigenkapital von 1.50
- PQ Inc hat Verschuldung / Eigenkapital von 1.50